I have a patient from the Philippines with a positive QuantiFERON test who reports receiving one pill daily for six months in [DATE] but cannot recall the medication name; was latent tuberculosis infection (LTBI) ever treated with a single‑pill daily regimen at that time?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Was LTBI Ever Treated with a Single Daily Pill in the Early 2000s?

Yes, your patient's report is entirely consistent with standard LTBI treatment from that era—she almost certainly received isoniazid (INH) 300 mg daily for 6 months, which was a single-pill regimen widely used and recommended at that time.

Historical Context and Treatment Standards

In the early 2000s, the standard LTBI treatment options included 1:

  • Isoniazid daily for 6-9 months (the most common regimen)
  • Rifampin plus pyrazinamide for 2 months (though this fell out of favor due to hepatotoxicity concerns)
  • Rifampin alone for 4 months (as an alternative)

The 6-month daily isoniazid regimen was explicitly recommended in the 2000 ATS/CDC guidelines 1. While 9 months was considered optimal, the guidelines specifically stated that "a 6-mo regimen also provides substantial protection and has been demonstrated to be superior to placebo" and noted that "health departments or other providers may prefer to concentrate efforts in ensuring the implementation of a 6-mo rather than a 9-mo course of isoniazid" 1.

The Single Pill Formulation

Isoniazid was available as a 300 mg single tablet during this period, making it literally "one pill" taken daily. This formulation was standard in many countries, though some regions (like Brazil at that time) only had 100 mg tablets requiring three pills daily 2. The Philippines likely had access to the 300 mg formulation, making your patient's recollection accurate.

Clinical Implications for Your Patient

Given this history:

  • She likely completed appropriate LTBI treatment with the 6-month isoniazid regimen
  • Her positive QuantiFERON now could represent:
    • Persistent immunologic memory from her treated LTBI (most likely)
    • New exposure/reinfection since her treatment
    • The original infection if treatment was incomplete or ineffective

Key Pitfalls to Avoid

Do not automatically retreat based solely on a positive QuantiFERON if she truly completed 6 months of daily isoniazid. IGRAs remain positive indefinitely in many treated individuals and do not distinguish between active infection, treated LTBI, and current LTBI 3, 4.

Your assessment should focus on:

  • Confirming treatment completion (did she actually take 6 months of daily medication?)
  • Ruling out active TB (symptoms, chest X-ray, sputum if indicated)
  • Assessing new risk factors (recent TB exposure, immunosuppression)
  • Evaluating for treatment failure indicators (if she had known exposure to drug-resistant TB)

If she completed treatment and has no new risk factors or evidence of active disease, retreatment is generally not indicated despite the positive QuantiFERON.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.